<i>In Silico</i> Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder
Our findings suggest that associated polymorphisms seem to have overlapping effects with addictive behaviors of Reward Deficiency Syndrome (RDS) and dopamine regulation. Consequently, GLP1R agonists may represent a double-edged sword, potentially triggering both antiaddictive effects and SI by exacerbating depressive phenotypes. Thus, we encourage the scientific community to perform further empirical clinical studies to confirm this proposed pathway.
Authors
- Jocelyn Ashford
- Panayotis K. Thanos (ORCID: https://orcid.org/0000-0002-5663-3478)
- Rossano Kepler Alvim Fiorelli (ORCID: https://orcid.org/0000-0001-5236-0903)
- Paul R. Carney (ORCID: https://orcid.org/0000-0001-6248-1493)
- Edward J. Modestino (ORCID: https://orcid.org/0000-0001-7611-5144)
- Eliot L. Gardner (ORCID: https://orcid.org/0000-0003-1541-3249)
- Colin Hanna
- Alireza Sharafshah (ORCID: https://orcid.org/0000-0001-8048-9587)
- David Baron (ORCID: https://orcid.org/0000-0001-7670-2613)
- Jag Khalsa (ORCID: https://orcid.org/0000-0002-6534-3616)
- Jean Lud Cadet (ORCID: https://orcid.org/0000-0001-5635-3524)
- Rajendra D. Badgaiyan (ORCID: https://orcid.org/0000-0001-5586-5114)
- Rene Cortese (ORCID: https://orcid.org/0000-0001-9262-7828)
- Abdalla Bowirrat (ORCID: https://orcid.org/0000-0001-8185-0688)
- Igor Elman (ORCID: https://orcid.org/0000-0002-1345-2677)
- Albert Pinhasov (ORCID: https://orcid.org/0000-0001-8116-4565)
- Brian Fuehrlein (ORCID: https://orcid.org/0000-0002-3202-8089)
- Catherine A. Dennen
- Sergio L. Schmidt (ORCID: https://orcid.org/0000-0001-7654-5507)
- Kenneth Blum
- Mark S. Gold
- Kai-Uwe Lewandrowski
- Gene Jack Wang
- Aryeh R Pollack
- Eric R. Braverman (ORCID: https://orcid.org/0000-0001-5525-8314)
Institutions
- Texas Tech University (US)
- Cambridge Health Alliance (US)
- National Institutes of Health (US)
- National Institute on Drug Abuse (US)
- Harvard University (US)
- George Washington University (US)
- Guilan University of Medical Sciences (IR)
- Washington University in St. Louis (US)
- VA Palo Alto Health Care System (US)
- Thomas Jefferson University Hospital (US)
- University of Missouri Health System (US)
- Yale University (US)
- Northeast Health (US)
- National Institute on Alcohol Abuse and Alcoholism (US)
- Desert Institute For Spine Care (US)
- NeuroGenetic Pharmaceuticals (United States) (US)
- Jacobs Institute (US)
- Cognitive Research (United States) (US)
- Fundación Universitaria Sanitas (CO)
- Curry College (US)
- Ariel University (IL)
- University at Buffalo, State University of New York (US)
- University of Missouri (US)
- Universidade Federal do Estado do Rio de Janeiro (BR)
- Jefferson College (US)
- Texas Tech University Health Sciences Center (US)
- Western University of Health Sciences (US)
Publication Details
- Journal
- Current Neuropharmacology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.2174/011570159x349579241231080602
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06